Vildagliptin Dosage and Clinical Evidence

Dosage Recommendations

• The recommended regimen is 50 mg taken twice daily, or 50 mg once daily when combined with a sulfonylurea to lower the risk of hypoglycemia【1】.

Evidence from Guidelines

• The 2024 American Diabetes Association (ADA) guidelines cite the VERIFY trial, showing that initial combination therapy with metformin and vildagliptin prolongs the time to treatment failure compared with sequential medication addition, supporting the use of vildagliptin 50 mg twice daily together with metformin from treatment initiation【1】.

Safety Profile

• According to the 2025 Diabetes Care review, DPP‑4 inhibitors such as vildagliptin provide intermediate glucose‑lowering efficacy, carry no hypoglycemia risk when used as monotherapy, and are weight‑neutral【2】.
• Pancreatitis cases have been reported with vildagliptin, but a causal relationship has not been established; the drug should be discontinued if pancreatitis is suspected【2】.